Mitochondrial dysfunction may represent one of the key cellular pathologies in Alzheimer’s disease and may be intimately related to its progression. Defective metabolism and increased generation of excess reactive oxygen species in mitochondria, as widely observed in Alzheimer's cases, can lead to mitochondrial DNA (mtDNA) oxidative modification and likely increases in rates of mtDNA mutations. Such molecular changes can enhance the mitochondrial and cellular pathology, especially in populations of neurons selectively vulnerable to oxidative stress.
The Mitochondrial Genomics and Metabolism (MGM) Core of the KU Azheimer's Disease Center was structured to provide unique resources and expertise to investigators who plan to probe mitochondrial changes in Alzheimer's disease and unravel the relationships between Alzheimer's and altered mitochondrial metabolism in white blood cells, platelets, neurons, glia, and muscle cells.
The role of the MGM Core is to:
MGM will assist investigators in studies on mitochondria obtained from the brain, muscle, white blood cells, and platelets of well-characterized cases of Alzheimer's, mild cognitive impairment (MCI), and age-matched controls. Specifically, MGM offers the following core resources and expertise for ADC investigators:
- Preparation, cataloging, and storage of mitochondria, protein extracts, DNA, and RNA from living and deceased subjects recruited by the Clinical Core
- Preparation and banking of cybrid lines using neuronal and platelet mitochondria obtained from living subjects
- Sequencing of mtDNA, determination of levels of mtDNA heteroplasmy, and measurements of mtDNA oxidation
Jan 13, 2021